Scarica l'app Stockscreener
72.13
1.93%
-1.42
Dopo l'orario di chiusura:
72.07
-0.06
-0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$73.55
Aprire:
$73.25
Volume 24 ore:
3.21M
Relative Volume:
0.90
Capitalizzazione di mercato:
$28.90B
Reddito:
$4.03B
Utile/perdita netta:
$576.20M
Rapporto P/E:
50.44
EPS:
1.43
Flusso di cassa netto:
$630.70M
1 W Prestazione:
-1.70%
1M Prestazione:
-19.78%
6M Prestazione:
+6.81%
1 anno Prestazione:
-48.45%
Intervallo 1D:
$71.47
$73.40
Intervallo di 1 settimana:
$71.47
$76.27
Portata 52W:
$62.34
$141.99
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
72.13 | 28.90B | 4.03B | 576.20M | 630.70M | 1.43 |
|
ABT
Abbott Laboratories
|
126.61 | 219.58B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
102.34 | 151.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
367.77 | 142.81B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.23 | 115.57B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.09 | 41.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
Dexcom’s FDA warning letter reveals unauthorized changes to sensors - MedTech Dive
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor - Yahoo Finance
DexCom, Inc. (DXCM) Announces Change in Independent Auditors - GuruFocus.com
DexCom appoints Deloitte as new auditor, replacing EY - Investing.com India
DexCom Names Jon Coleman as Chief Commercial Officer - Marketscreener.com
DexCom names Jon Coleman as new chief commercial officer - Investing.com India
FDA warns Dexcom over continuous glucose monitor testing - Modern Healthcare
Dexcom Appoints Jon Coleman As Chief Commercial Officer - Marketscreener.com
Dexcom Appoints Jon Coleman as Chief Commercial Officer - Bluefield Daily Telegraph
Healthcare Pioneer Dexcom Taps 30-Year Industry Leader to Drive Global Growth - StockTitan
Citi maintains Buy rating on DexCom stock with $104 target By Investing.com - Investing.com UK
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom - 01Net
A unique opportunity to say thank you - The Persistent Pursuit
DexCom (DXCM): 3 Reasons We Love This Stock - Yahoo Finance
DexCom Faces Short-Term Challenges, But Market Growth Prospects Remain Strong: Analyst - MSN
Is DexCom Gaining or Losing Market Support? - Benzinga
Dexcom shares 15-day CGM data; Tandem posts Type 2 pivotal data - MedTech Dive
Dexcom director Heller sells $24,756 in stock By Investing.com - Investing.com Canada
Dexcom director Heller sells $24,756 in stock - Investing.com
DexCom Inc. stock outperforms competitors on strong trading day - MSN
Dexcom Welcome Renée Galá to its Board of Directors - MPO-mag
Buy, Sell, Or Hold DXCM Stock At $70? - Forbes
Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care - 01Net
Dexcom's Game-Changing CGM Achieves Industry-Best 8.0% MARD, Doctors Choose Tech Over Drugs - StockTitan
DexCom, Inc. (DXCM): Among the Best Diabetes Stocks to Buy According to Billionaires - Yahoo Finance
Insulet's Game-Changing Automated Insulin System Expands Global Reach to Australia, Belgium, Canada - StockTitan
74,737 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by Proficio Capital Partners LLC - Defense World
Dexcom’s chief legal officer sells $914,941 in stock By Investing.com - Investing.com Australia
Dexcom CFO sells shares for over $844,000 By Investing.com - Investing.com Australia
Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management - Business Wire
10 Best Diabetes Stocks To Buy According to Billionaires - Insider Monkey
Dexcom EVP Jacob Steven Leach sells stock for $990,670 By Investing.com - Investing.com Australia
Dexcom’s chief legal officer sells $914,941 in stock - Investing.com
Dexcom’s EVP Sadie Stern sells $786,567 in stock - Investing.com
Looking At DexCom's Recent Unusual Options Activity - Benzinga
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter - Yahoo Finance
William Blair Forecasts DexCom’s Q1 Earnings (NASDAQ:DXCM) - Defense World
Is DexCom Stock Underperforming the Dow? - MSN
Non-Invasive Blood Glucose Monitoring Devices Market Is Booming Worldwide 2025-2032:Dexcom, Inc,Opticology - EIN News
Is DexCom Stock Underperforming The Dow? - Barchart
Head to Head Contrast: DexCom (NASDAQ:DXCM) vs. Biotricity (NASDAQ:BTCY) - Defense World
Dexcom’s CFO Sylvain sells shares worth $516,830 By Investing.com - Investing.com South Africa
Dexcom’s CFO Sylvain sells shares worth $516,830 - Investing.com India
Analysts say Dexcom’s FDA warning unlikely to impact 2025 revenue - Yahoo Finance
DexCom Options Trading: A Deep Dive into Market Sentiment - Benzinga
SBI Securities Co. Ltd. Makes New Investment in DexCom, Inc. (NASDAQ:DXCM) - Defense World
DexCom continues decline following FDA warning letter - MSN
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Dexcom receives warning letter based on FDA inspections of 2 plants - MedTech Dive
DexCom Stock Drops as Diabetes Devices Maker Gets FDA Warning Letter - Investopedia
DexCom, Inc. Appoints Renée Galá as A Director -March 10, 2025 at 08:31 am EDT - Marketscreener.com
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.30%
0.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):